SARS News and Research

RSS

Incidence and risk factors of an invasive fungal lung infection among COVID-19 patients

Study reveals 0.4%-2.7% incidence of COVID-19-associated pulmonary aspergillosis in severe patients, highlighting significant mortality risks and risk factors.

24 Sep 2024

Human challenge study reveals lasting cognitive decline after mild COVID-19

Researchers from the UK conducted the first human challenge study of SARS-CoV-2, revealing long-lasting cognitive deficits in unvaccinated participants infected with the virus, especially in memory and executive function.

23 Sep 2024

Research reveals a disconnect between patient expectations and care for long COVID

"Long COVID" is the continuation or development of new symptoms three months after initial SARS-CoV-2 infection.

23 Sep 2024

Researchers identify new oscillatory patterns in COVID-19 cases across the U.S.

Researchers discovered previously unrecognized oscillatory trends in COVID-19 cases across the U.S., particularly a north-south oscillation around the 37°-38° north latitude. These patterns highlight the complexity of pandemic dynamics and the importance of understanding regional disease transmission.

22 Sep 2024

Study identifies wildlife species likely involved in the origin of SARS-CoV-2

A new international study provides a shortlist of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019.

20 Sep 2024

Wastewater monitoring proves effective for tracking foodborne pathogens

First used in the 1940s to monitor for polio, wastewater surveillance proved such a powerful disease monitoring tool that the U.S. Centers for Disease Control and Prevention (CDC) established the National Wastewater Surveillance System to support SARS-CoV-2 monitoring in September of 2020.

20 Sep 2024

New research strengthens the case for a zoonotic origin of COVID-19

A new international collaborative study provides a list of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019. The study is based on a new analysis of metatranscriptomic data released by the Chinese Center for Disease Control and Prevention (CDC).

20 Sep 2024

New method identifies biomarkers in wastewater using origami-paper sensors

Researchers at Cranfield University have developed an innovative new method for identifying biomarkers in wastewater using origami-paper sensors, enabling the tracking of infectious diseases using the camera in a mobile phone.

19 Sep 2024

Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

18 Sep 2024

Antibiotic resistance threatens millions of lives worldwide

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.

18 Sep 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Long COVID patients maintain robust immune memory two years after infection

Researchers discovered that SARS-CoV-2-specific T and B cells in long COVID patients are maintained for two years, similar to fully recovered individuals, offering insights into long-term immunity.

17 Sep 2024

Monoclonal antibodies could help provide an answer to antimicrobial resistance

Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the growing problem of antimicrobial resistance, say scientists.

16 Sep 2024

SARS-CoV-2 exposure stabilizes BMI in infected adults while others see shifts

Real-world study reveals how SARS-CoV-2 infection influences body mass index, showing stable BMI in infected individuals while unexposed and pre-pandemic groups saw changes.

16 Sep 2024

Cardiovascular risks of COVID-19 antivirals

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.

16 Sep 2024

Australians with health conditions strongly advocate for ongoing COVID-19 safety measures

Study reveals that over half of Australians with underlying health conditions continue to support and follow COVID-19 mitigation measures, highlighting the ongoing public health concerns despite eased government mandates.

15 Sep 2024

NIH funds new research to combat emerging viruses

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

14 Sep 2024

New research network focuses on high-priority viruses

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises - both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program, pending the availability of funds.

14 Sep 2024

Evolution of vaccine adjuvants from empirical discovery to rational design

Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.

13 Sep 2024

Study reveals how SARS-CoV-2 triggers diabetes by destroying pancreatic cells

Researchers from Weill Cornell Medicine have used a cutting-edge model system to uncover the mechanism by which SARS-CoV-2, the virus that causes COVID-19, induces new cases of diabetes, and worsens complications in people who already have it.

13 Sep 2024